Navigation Links
Pharmasset to Webcast an Investor Event From the EASL Meeting
Date:3/28/2011

PRINCETON, N.J., March 28, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the European Association for the Study of the Liver (EASL) on Saturday, April 2, 2011 starting at 8:00pm CET. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at EASL.

To access a simultaneous webcast of this event via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

PSI-7977

Abstract (oral)

"Once Daily PSI-7977 plus PegIFN/RBV: Rapid Virologic Suppression in Treatment Naive Patients with HCV GT2/GT3 in a Phase 2b Trial" will be presented in the HCV Drug Development session on Friday, April 1 at 4:15pm CET. Authors of the study are Lalezari, J. et al.

Abstract 1372

"Once Daily PSI-7977 Plus Peg-IFN/RBV in HCV GT1: 98% Rapid Virologic Response, Complete Early Virologic Response: The PROTON Study" will be presented in a late breaker poster session on Thursday, March 31. Authors of the study are Nelson, DR. et al.

PSI-938

Abstract 1235

"PSI-352938, A Novel Purine Nucleotide Analog, Exhibits Potent Antiviral Activity and No Evidence of Resistance in Patients With HCV Genotype 1 Over 7 Days" will be presented in a poster session on Saturday, April 2. Authors of the study are Rodriguez-Torres M. et al.

Abstract 1217

"Mechanism of HCV Replicon Resistance to PSI-352938, a Cyclic Monophosphate Prodrug of 2'-alpha-F-2'-beta-C-Methylguanosine" will be presented in a poster session on Saturday, April 2. Authors of the study are Lam A. et al.

Abstract 1370

"Once Daily Dual-Nucleotide Combination of PSI-938 and PSI-7977 Provides 94% HCV RNA <LOD at Day 14: First Purine/Pyrimidine Clinical Combination data (The NUCLEAR Study)" will be presented in a late breaker poster session on Thursday, March 31. Authors of the study are Lawitz E. et al.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that is currently dosing in two Phase 2b studies in patients with HCV genotypes 1, 2, or 3, and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and a 14-day combination study with PSI-7977. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development.

Pegasys® and Copegus® are registered trademarks of Roche.

Contact
   Richard E. T. Smith, Ph.D.
   VP, Investor Relations and Corporate Communications
   Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset to Present at Three Upcoming Investor Conferences
2. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
3. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
4. Pharmasset Announces Exercise of Underwriters Overallotment Option
5. Pharmasset Prices Public Offering of Common Stock
6. Pharmasset Announces Proposed Public Offering of Common Stock
7. Pharmasset Reports Positive Results from its HCV Clinical Programs
8. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
10. Pharmasset to Webcast an Investor Event from the AASLD Meeting
11. Pharmasset to Present at the JMP Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Calif. , Jan. 20, 2017 ARMO ... 1b clinical data on the Company,s lead investigational immuno-oncology ... Symposium, co-sponsored by the American Society of Clinical Oncology ... San Francisco, CA. "AM0010 ... activated CD8 + T cells in the blood ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
(Date:1/20/2017)... Research and Markets has announced the addition of the ... Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver Panel, Renal Panel, ... report to their offering. ... The global clinical laboratory testing market is expected to ... solutions on the grounds of maximum efficiency and minimum error is ...
Breaking Medicine Technology:
(Date:1/23/2017)... Los Angeles, California (PRWEB) , ... January 23, 2017 , ... ... “Golden Era” principles, has added Mr. Olympia Classic Physique bodybuilder Breon Ansley to its ... back began competing as a bodybuilder in 2012 and in less than a year ...
(Date:1/23/2017)... ... ... a story of love and redemption, hope and uncertainty as a girl makes her ... Inn at the Mill” is the creation of published author, Lois Kulp, who was born ... Berks County on Crow Hill. The inn, the mill and "Post Yokel" are ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Life Under Blankets”: an ... an early age. “Life Under Blankets” is the creation of published author, Kimberly Mitchell, ... Campus in Chicago. She went on to pursue a master’s degree in education in ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to take an exotic ... the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of Zanzibar, a Tanzanian ... Oil and moisturizing vegetal coral to create this gentle, velvety body cream to envelop ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals and ... a simple test will take days to arrive to the end customer, having to ... access to their lab tests, bypassing the cost and delay of traditional means. Now ...
Breaking Medicine News(10 mins):